GRACE: An open-label, multicenter trial to compare the efficacy, safety, and tolerability of PREZISTA (darunavir)/ritonavir by gender and race, when administered in combination with an individually optimized background regimen over a 48-week treatment period
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Darunavir (Primary) ; Antiretrovirals; Ritonavir
- Indications HIV-1 infections
- Focus Adverse reactions; Therapeutic Use
- Acronyms GRACE
- Sponsors Tibotec Inc
- 21 Sep 2010 Data from GRACE will be published in the September 21st issue of the Annals of Internal Medicine, according to a Tibotec Therapeutics media release.
- 21 Sep 2010 Results published in Annals of Internal Medicine.
- 15 Sep 2009 Results stratified by race have been reported at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 2009.